ArticleUrology2018

The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.

Lauren P Wallner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.